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Abstract: Medical device-associated staphylococcal infections are a common and challenging 
problem. However, detailed knowledge of staphylococcal biofilm dynamics on clinically relevant 
surfaces is still limited. In the present study, biofilm formation of the Staphylococcus aureus ATCC 
25923 strain was studied on clinically relevant materials—borosilicate glass, plexiglass, 
hydroxyapatite, titanium and polystyrene—at 18, 42 and 66 h. Materials with the highest surface 
roughness and porosity (hydroxyapatite and plexiglass) did not promote biofilm formation as 
efficiently as some other selected materials. Matrix-associated poly-N-acetyl-β-(1-6)-glucosamine 
(PNAG) was considered important in young (18 h) biofilms, whereas proteins appeared to play a 
more important role at later stages of biofilm development. A total of 460 proteins were identified 
from biofilm matrices formed on the indicated materials and time points—from which, 66 proteins 
were proposed to form the core surfaceome. At 18 h, the appearance of several r-proteins and 
glycolytic adhesive moonlighters, possibly via an autolysin (AtlA)-mediated release, was 
demonstrated in all materials, whereas classical surface adhesins, resistance- and virulence-
associated proteins displayed greater variation in their abundances depending on the used material. 
Hydroxyapatite-associated biofilms were more susceptible to antibiotics than biofilms formed on 
titanium, but no clear correlation between the tolerance and biofilm age was observed. Thus, other 
factors, possibly the adhesive moonlighters, could have contributed to the observed chemotolerant 
phenotype. In addition, a protein-dependent matrix network was observed to be already well-
established at the 18 h time point. To the best of our knowledge, this is among the first studies 
shedding light into matrix-associated surfaceomes of S. aureus biofilms grown on different clinically 
relevant materials and at different time points. 
Keywords: Staphylococcus aureus; biofilm matrix; clinical material; exopolysaccharide; proteins; 
surfaceome  
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1. Introduction 
Implanted medical devices have been consistently shown to improve the quality of life of 
patients suffering from critical conditions such as the destruction of joints [1]. Increasing life span 
and evolving medical sciences have accelerated the use of such devices. However, paradoxically, this 
trend has also increased the propensity to device-associated infections. In joint replacements, 
infection rates have been estimated to be approximately 1.7% in hip, 2% in knee and 9% in ankle 
prostheses [2]. In addition, 5–10% of inserted internal fixation devices can typically become infected 
[3]. Elderly, obese, malnourished, diabetic and rheumatic patients and near-surface body inserts with 
poor soft tissue coverage are most vulnerable to such infections. Medical device-associated infections 
are common complications of implantation surgery caused by material-colonizing microbial 
communities, also known as biofilms [1]. 
Staphylococcal spp. biofilms are one of the frequent causes of certain medical device-associated 
infections, such as infections related to intravenous catheters [4,5], cardiac pacemakers [6] and 
mammary implants [7,8]. In prosthetic joint infections, especially Staphylococcus aureus is largely 
responsible for early post-interventional infection types [9]. Biofilms refer to complex communities 
of bacteria, which can be attached to a surface or form aggregates without attachment to any surface. 
Biofilms differ from free-floating cells by slow growth and tolerance to antibiotics and immune cells 
of the host [10–13]. Freely floating bacteria are responsible for colonizing new niches, while the 
biofilm lifestyle, preferred by most of the bacteria, serves as a survival strategy against external 
threats [14]. Increased adaptation, adherence and antibiotic tolerance are characteristic features of the 
bacterial biofilm. These features are to a great extent connected to a slimy structure surrounding the 
bacterial cell community known as the biofilm matrix, which forms approximately 90% of the biofilm 
dry mass and it is comprised of hydrated extracellular polymeric components (EPS), such as 
exopolysaccharides, proteins, lipids and nucleic acids [15]. The biofilm matrix is likely to change as 
biofilms develop over time, and it is also different between biofilms formed on different surfaces. 
Those changes in the biofilm matrix are likely crucial for understanding antibiotic tolerance and 
designing better anti-biofilm therapies. However, the dynamics of such changes have been poorly 
investigated, thus far. 
Bacteria may colonize indwelling medical devices during implantation or at later stages by 
hematogenous seeding. After implantation, medical devices are promptly coated by host proteins, 
involving fibrinogen, fibronectin and fibrin, which can facilitate adhesion of bacteria like 
Staphylococcus aureus that express receptors for binding these plasma proteins [16,17]. The implant-
induced changes in the host, such as reduced blood flow and impaired activity of lymphocytic and 
phagocytic cells, are other factors that can also promote the biofilm formation on medical devices [1]. 
Besides, some substrate materials such as polymethyl methacrylate, acrylic glass (PMMA) can 
intrinsically contribute to biofilm formation by hampering the complement and reducing leukocytic 
activity. Notably, phagocytic cells often focus on degrading the medical device itself, not the bacteria. 
Strategies to cope with such infections have involved systemically administered antibiotics [18]. 
However, achieving an adequate concentration of the antibiotic at the biofilm infection site is difficult 
due to reduced local tissue perfusion and compromised vasculature [19,20]. Thus, removal of the 
device and debridement of the necrotic tissue is often required in conjunction with the insertion of a 
new medical device, which often leads to revision surgeries and prolonged hospitalization periods 
with a high risk for re-infections [3,21]. A systemic antibiotic prophylaxis during the time of the 
surgery together with the coating of the inserted devices have been suggested among the strategies 
to improve clinical outcomes with implanted medical devices [18]. 
A wide range of different implant materials are used in orthopedics. Despite the intensive 
research currently being performed on different technologies for incorporating antimicrobial agents 
[22–32], only a few studies investigating biofilm formation on different clinically relevant 
implantation materials have been published [33–38]. The dynamic changes associated with biofilm 
growth [39] make biofilm eradication from clinical materials even more challenging. As structural 
and functional features of biofilms are greatly dependent on the material and the biofilm growth 
conditions [38,40–41], there is an obvious demand for comprehensive studies investigating the 
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structural and functional features of the prosthetic materials together with biofilm dynamics on these 
materials. In this context, the cell surface-associated adhesins have attracted great interest, as many 
of these can contribute to protein-mediated biofilm formation [39,42–46]. Recently, an 
unacknowledged group of surface-associated proteins, i.a., moonlighting virulence factors and 
cytoplasmic proteins embedded in the staphylococcal biofilm matrix, was proposed to form a new 
molecular mechanism conferring increased stability for biofilm population [47]. High levels of 
intracellular cytoplasmic proteins and, to a much lesser extent, extracellular or cell-surface adhesins 
have also been identified from in vivo biofilm matrices using a rat model of orthopedic implant-
associated chronic S. aureus infection [48]. Whether these moonlighters play a role during the 
formation of S. aureus biofilms on different prosthetic materials is not yet clear. 
Thus, the aim of the present study was to compare the biofilm characteristics of a S. aureus 
biofilm-forming model strain ATCC 25923 (also known as strain Rosenbach or Seattle 1945) [49] on 
different clinically pertinent substrates, involving borosilicate glass, plexiglass, hydroxyapatite and 
titanium, using polystyrene as the reference material. Borosilicate glass (G) has been traditionally 
used in artificial hip joints, bone cements, dental composite materials, prosthetic eyes and breast 
implants [50,51], while plexiglass (PG) is used in bone cements [52]. Joint implants are made of 
titanium alloys (TI) due to their biocompatibility and corrosion resistance, while hydroxyapatite 
(HA), a known mineral component of bones, is used to coat medical devices for improving the 
integration of the implant with newly formed bone [53]. The present study focused on (1) comparing 
the susceptibility of these clinically relevant surfaces to biofilm formation, (2) studying the time-
dependent variations in exopolysaccharide and protein compositions of the biofilms on the indicated 
materials, and (3) identifying the core surfaceome (proteins present in all aged biofilms (18, 42, and 
66 h) on every material) contributing to adherence/adherent growth. The present study demonstrates 
a number of material- and time point-dependent surfaceome changes. As a main finding, matrix-
associated poly-N-acetyl-β-(1-6)-glucosamine (PNAG) was regarded as important in young (18 h) 
biofilms, whereas proteins had a more pivotal role at later stages of biofilm development. 
2. Materials and Methods 
2.1. Materials 
Tryptic soy agar (TSA) and tryptic soy broth (TSB) were acquired from Lab M Limited 
(Lancashire, UK), while sucrose was from Merck (Darmstadt, Germany). Sequencing-grade modified 
trypsin (porcine) was purchased from Promega Corp. (Madison, WI, USA). Wheat germ agglutinin 
Alexa Fluor® 488 conjugate (WGA) was obtained from Invitrogen™, Thermo Fisher Scientific 
(Eugene, OR, USA). Dimethyl sulphoxide (DMSO) was purchased from VWR International 
(Fontenay-sous-Bois, France) and phosphate-buffered saline (PBS) was supplied by Lonza (Verviers, 
Belgium). Trifluoroacetic acid (99%), triethylammonium bicarbonate buffer (TEAB; 1.0 M, pH 8.5), 
Tween® 20, vancomycin hydrochloride hydrate, penicillin G sodium salt, levofloxacin and 
doxycycline hydrochloride were purchased from Sigma-Aldrich (Steinheim, Germany). 
2.2. Atomic Force Microscopy (AFM) 
The topography of the material surfaces (borosilicate glass, G; plexiglass, PG; hydroxyapatite, 
HA; titanium, TI and polystyrene, PS) was characterized with an NTegra Prima AFM (NT-MDT, 
Moscow, Russia) in an intermittent contact mode by using Au-coated NSG10 (NT-MDT, Moscow, 
Russia) probes with a nominal tip curvature radius of 10 nm and a force constant of 3.1–37.6 N/m. A 
scan rate of 0.3–0.5 Hz was used. Image analysis was conducted by using the Scanning Probe Image 
Processor software (SPIP, Image Metrology, Hørsholm, Denmark). Captured topographs were 
processed with Gaussian (ISO 11562) filtering. 
2.3. Bacterial Culture and Biofilm Formation 
The clinical strain Staphylococcus aureus ATCC 25923 was cultured in TSB at 37 °C under aerobic 
conditions with shaking (220 rpm) to reach the exponential phase, to a concentration of 108 CFU·mL−1. 
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The bacterial concentration was estimated by measuring optical density at 595 nm (Varioskan™ LUX 
Multimode Microplate Reader, Thermo Scientific, Vantaa, Finland) and later confirmed by 
calculating colony-forming units (CFUs) on TSA plates. Biofilms were formed on 96-well plates (96-
WPs) (Nunclon™ Δ surface polystyrene plates, Nunc™, Roskilde, Denmark) or on coupons made of 
borosilicate glass (G), plexiglass (PG), titanium (TI) with dimensions: 0.4 cm height, 1.27 cm diameter; 
and hydroxyapatite (HA) with dimensions: 0.25 cm height, 1.27 cm diameter (BioSurface 
Technologies Corporation, Bozeman, MT, USA). For the experiments with coupons, they were placed 
in a polystyrene 12-WP (Costar®, flat bottom, well diameter 2.26 cm; Corning Inc., Corning, NY, USA). 
For the experiments performed in 12-WPs (with the coupons on them) or 96-WPs, 2.5 mL or 200 µL 
of the bacterial suspension (106 CFU·mL−1) were used, respectively. The plates were incubated at 37 
°C under aerobic conditions with shaking (150 rpm) for 18, 42 or 66 h (the incubation times were 
based on [54]). The media of the 42-h-old biofilms were changed after 18 h of incubation, whereas the 
media of the 66-h-old biofilms were refreshed at 18 and 42 h. 
2.4. Quantification of Biofilm Formation on Different Materials 
S. aureus ATCC 25923 was grown on polystyrene (PS) (in 96-WP) or on borosilicate glass (G), 
plexiglass (PG), hydroxyapatite (HA) and titanium (TI) coupons in 12-WP, as described above. After 
18, 42 or 66 h, the biofilms formed on G, PG, HA or TI coupons were disaggregated for quantification 
as follows. First, the coupons were soaked in the medium (TSB) to detach planktonic and loosely 
attached bacteria, and then transferred into Falcon tubes of 50 mL containing 1 mL of 0.5% (w/v) 
Tween® 20-TSB solution. In contrast, biofilms grown on 96-WPs were washed once with 200 µL of 
TSB, and 200 µL of Tween® 20-TSB solution was added on wells. The tubes and the 96-WPs were 
sonicated in a water bath in Ultrasonic Cleaner 3800 (Branson Ultrasonics, Danbury, CT, USA) at 25 
°C, 35 kHz, for 5 min. Serial dilutions (10−1–10−8) were performed from the resulting bacterial 
suspensions onto TSA plates. Size differences between coupons and 96-WPs were taken into account 
by measuring colony-forming units (CFU) per volume (mL) and area of bacterial attachment on the 
different surfaces (cm2) and transforming the values of CFU·(mL·cm2)–1 to a log10 scale. 
2.5. Quantification of Matrix-Associated Poly-N-Acetyl-β-(1-6)-Glucosamine 
For quantifying matrix poly-N-acetyl-β-(1-6)-glucosamine (PNAG), S. aureus ATCC 25923 
biofilms were grown in 96-WPs and on coupons in 12-WPs for 18, 42 and 66 h, as described above. 
The previously reported WGA staining protocol [54] was applied with two modifications: a lower 
concentration (2.5 µg·mL−1) of WGA conjugate was used based on [55] and 100% DMSO was used to 
replace 33% acetic acid, which is not compatible with acid-unbearable materials, such as HA. The 
selection of 100% DMSO was based upon initial tests where a lower concentration of acetic acid (10% 
acetic acid), 96% ethanol and 100% DMSO were tested (acquired assay quality parameters for DMSO: 
screening window coefficient Z’ factor = 0.431; signal to noise (S/N) = 5.4; signal to background (S/B) 
= 9.2) 
First, the 96-WPs were washed once with 200 µL of PBS, while the coupons were briefly soaked 
once in PBS, to detach planktonic and loosely attached cells. Then, WGA in PBS (2.5 µg·mL−1) was 
added onto 96-WPs (200 µL) or onto coupons (500 µL) in 24-WPs (Nunclon™ Δ surface, Nunc™, 
Roskilde, Denmark) and incubated in the darkness at 4 °C for 2 h. After the incubation, the biofilms 
were washed three times with PBS and dried at room temperature (RT) for 15 min. Next, 200 µL of 
DMSO was added into the 96-WPs. The coupons were transferred into Falcon tubes of 50 mL, 
containing 1.3 mL (for G, PG and TI) or 1.11 mL (for HA coupons; smaller volume was due to the 
smaller size of these coupons) of DMSO. The plates and the tubes were sonicated in a water bath at 
25 °C, 35 kHz, for 30 s. Following an incubation at 37 °C for 1 h, the sonication step was repeated. 
Finally, 200 µL of the remaining suspensions from Falcon tubes were transferred onto a 96-WP to 
measure top fluorescence with Varioskan™ LUX Multimode Microplate Reader (λexcitation = 495 nm; 
λemission = 520 nm). Before measuring the fluorescence signal from biofilms formed on 96-WPs, the 
resulting suspensions were diluted 1:10 to be in correspondence with the coupon surface area. 
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2.6. Fluorescence Imaging 
These experiments were performed with S. aureus ATCC 25923 biofilms grown on G coupons, 
stained with WGA as indicated above. After the 2-h-long incubation period (4 °C, in the darkness), 
the unbound dye was removed, and images of the coupons on Petri dishes were acquired with an 
Invitrogen™ EVOS® FL Imaging System (Life Technologies™, Eugene, OR, USA) using the Green 
Fluorescent Protein (GFP) light cube (λexcitation = 470/22 nm; λemission = 510/42 nm) and a 20× objective. 
2.7. Trypsin Shaving of Matrix-Associated Proteins 
Before protein identification, biofilm viability with and without the trypsin treatment was first 
assessed to exclude possible effects of trypsin on biofilm integrity. Biofilms were grown on G coupons 
in 12-WPs and then transferred into Falcon tubes (50 mL) containing 1 mL of 100 mM acetate buffer 
(pH 4.7), a condition preventing the release of the adhesive moonlighting proteins [56]. The tubes 
were sonicated (25 °C, 35 kHz, 5 min) and detached bacterial cells were collected by centrifugation (4 
°C, 4000× g, 2 min). The cells were suspended in 110 µL of 100 mM TEAB containing 16% sucrose 
(TEAB-sucrose (16%); pH 8.5) with and without trypsin (at a final concentration of 51.9 ng·µL−1), and 
the mixtures were incubated (37 °C, 15 min). Next, the cells were serially diluted in TSB and plated 
onto TSA to determine CFUs. The number of viable counts remained the same in both samples, 
excluding the possibility of trypsin-induced cell lysis (Figure S1) and confirming the suitability of the 
shaving conditions for trypsin shaving. 
Biofilm cells for trypsin shaving were prepared in duplicates for each substrate and time point 
as follows. Biofilms attached to coupons were first rinsed with TSB to remove planktonic bacteria and 
transferred onto 12-WPs. There, the cells were scraped off from the coupon surface into 100 mM 
acetate buffer (4 °C, pH 4.7) using a sterile plastic stick. In the case of biofilms formed on PS, the 
biofilms were also rinsed with TSB first and scraped off from 96-WPs into 100 mM acetate buffer. In 
all cases, cells were collected by centrifugation (4 °C, 4000× g, 2 min) and suspended in 110 µL of 100 
mM TEAB-sucrose (16%) [57] and trypsin (at a final concentration of 51.9 ng·µL−1). After the trypsin 
treatment (37 °C, 15 min), cells were first removed by centrifugation (RT, 4000× g, 2 min) and 
digestions were further purified through cellulose acetate membranes (pore size 0.22 µm, Costar® 
Spin-X Centrifuge Tube Filter, Corning Inc., Corning, NY, USA) by centrifugation (RT, 16000× g, 2 
min). Digestions incubated at 37 °C for 16 h were blocked by adding trifluoroacetic acid to a final 
concentration of 0.6%. Concentrations of released proteins/peptides were measured using low-
volume photometric quantification at 280 nm, with a µDrop™ Plate (Thermo Scientific, Vantaa, 
Finland) on a Varioskan™ LUX Multimode Reader (Thermo Scientific, Vantaa, Finland). 
2.8. Identification of Trypsin-Released Proteins/Peptides by LC–MS/MS 
Tryptic peptides were purified and concentrated using ZipTips (C18; Millipore ®, Merck KGaA, 
Darmstadt, Germany) and peptides were analyzed essentially as described previously [58]. Briefly, 
an equal amount of the purified tryptic peptides was submitted to an Easy-nLC 1000 Nano-LC system 
(Thermo Scientific, Vantaa, Finland) coupled to a quadrupole Orbitrap mass spectrometer (Q 
Exactive™, Thermo Scientific, Bremen, Germany) equipped with a nanoelectrospray ion source 
(Easy-Spray™, Thermo Scientific, Vantaa, Finland). Liquid chromatography separation was 
performed in an Easy-Spray™ column of 25 cm bed length (C18, 2 µm beads, 100 Å, 75 µm inner 
diameter, Thermo Scientific), using a flow rate of 300 nL/min. The peptides were eluted with a 2–30% 
gradient of solvent (composed of 100% acetonitrile and 0.1% formic acid) in 60 min. Acquired MS 
raw data were processed using the MaxQuant version 1.6.2.1 [59] with built-in Andromeda search 
engine [60]. Database searches were conducted against the UniProt S. aureus protein database 
(https://www.uniprot.org/). In these searches, carbamidomethyl (C) was set as a fixed and 
methionine oxidation as a variable modification. First search peptide tolerance of 20 ppm and main 
search error of 4.5 ppm were used. Trypsin without proline restriction enzyme option was used, with 
two allowed miscleavages. The minimal unique + razor peptides number was set to 1, and FDR to 
0.01 (1%) for peptide and protein identification. Known contaminants provided by MaxQuant, and 
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proteins identified as “reverse” and “only identified by site” were discarded from further data 
analyses. Only proteins that could be identified in both replica samples were included in data set 
comparisons. 
2.9. Chemotolerance Assays 
S. aureus ATCC 25923 biofilms were grown on HA and TI coupons in 12-WPs for 18 and 66 h, as 
previously described in Section 2.3. After the incubation, the chemotolerance assay was performed 
essentially as described previously [28]. The coupons were soaked in TSB to detach planktonic cells 
and transferred onto 12-WPs containing 2.5 mL of 2.0 µM penicillin G (0.71 µg/mL), 90.0 µM 
levofloxacin (32.5 µg/mL), 4.0 µM doxycycline (1.92 µg/mL) or 5.0 µM vancomycin (7.43 µg/mL) or 
TSB (as a negative control). The coupons were exposed to the indicated antibiotics for 2 or 24 h at 37 
°C, under aerobic conditions with shaking (150 rpm). After the treatment, biofilms were quantified 
as in Section 2.4. A combination treatment involving trypsin (51.9 ng·µL−1) and 90 µM levofloxacin 
was also tested. Therein, biofilms were formed on HA for 18 and 66 h, as above. After the incubation 
periods, the coupons were soaked in TSB and transferred onto a 24-WP containing trypsin in buffer 
(35 µL of trypsin in 350 µL of 100 mM TEAB-sucrose (16%)) or mere buffer (385 µL of 100 mM TEAB-
sucrose (16%), as a negative control). The 24-WPs were incubated at 37 °C for 15 min, as described in 
Section 2.7. Next, the coupons were soaked in TSB, and transferred onto the 12-WP containing 2.5 mL 
of 90 µM levofloxacin. The coupons were incubated with the antibiotic at 37 °C under aerobic 
conditions with shaking (150 rpm) for 24 h. As a second control, biofilms were grown in TSB under 
similar conditions for 24 h and 15 min. Biofilm formation on the materials was assessed as in Section 
2.4. The anti-biofilm effect of the antibiotics is expressed as a logarithmic reduction of the bacterial 
burden [61], using equation (1): 
𝑙𝑜𝑔𝑅 = 𝑙𝑜𝑔ଵ଴〈(𝐶𝐹𝑈/𝑚𝐿)௖௢௡௧௥௢௟〉 − 𝑙𝑜𝑔ଵ଴〈(𝐶𝐹𝑈/𝑚𝐿)௖௢௠௣௢௨௡ௗ〉 (1) 
where 〈∙〉 denotes averaging over samples. 
2.10. Data Processing and Statistical Analysis 
For the optimization of the WGA staining protocol (Section 2.5), the following statistical 
parameters were used: screening window coefficient Z′ factor, signal to noise (S/N) and signal to 
background (S/B) (according to equations 2–4) [54,62–63]. 
𝑍ᇱ = 1 − (3 𝑥 𝑆𝐷௠௔௫ + 3 𝑥 𝑆𝐷௠௜௡)|𝑋௠௔௫ − 𝑋௠௜௡|  (2) 
𝑆
𝑁 =
𝑋௠௔௫ − 𝑋௠௜௡
(𝑆𝐷௠௔௫ଶ + 𝑆𝐷௠௜௡ଶ)ଵ/ଶ
 (3) 
𝑆
𝐵 =  
𝑋௠௔௫
𝑋௠௜௡  (4) 
One-way analysis of variance comparisons and Tukey (for equal variances) and Games–Howell 
(for unequal variances) post-tests were executed using IBM SPSS Statistics (SPSS Inc., Chicago, IL, 
USA, version 24.0 for Windows). In paired comparisons, the unpaired t-test with Welch′s correction 
was used (GraphPad Software, Prism, La Jolla, CA, USA, version 7.0 for Windows). p < 0.05 was 
considered statistically significant and p < 0.001 statistically highly significant. Each test was 
performed at least in duplicate. 
SPSS was also used in multivariate statistical analyses of the protein identification data, using 
average relative intensity values obtained for proteins identified in both biological replicates. The 
values of the commonly identified proteins were log2-transformed, and principle component analysis 
(PCA; based on the correlation matrix) was performed using Oblimin rotation with Kaiser 
Normalization. 
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3. Results 
3.1. HA and PG Exhibited the Largest Surface Roughness 
AFM topographical images of 96-well plates (made of polystyrene; PS) and borosilicate glass 
(G), plexiglass (PG), hydroxyapatite (HA) and titanium (TI) coupons are shown in Figure 1. Materials 
PG and HA are the most heterogeneous and uneven surfaces, whereas TI, PS and G appear to be 
much smoother. Roughness analysis of the AFM images provided more quantitative insights into the 
differences between the substrates (Table 1 and Figure S2). The surface area ratio (Sdr) describes the 
roughness-induced increment of the interfacial surface area relative to the area of the projected flat 
plane, while Vv illustrates the void volume, describing surface porosity. The surfaces of HA and PG 
showed the largest roughness values (Sdr = 58 ± 10% and 123 ± 20%; Vv = 0.75 ± 0.08 µm3/µm2 and 0.62 
± 0.07 µm3/µm2, respectively) (Table 1). The smoothest surface was observed to be G (Sdr = 0.3 ± 0.1%; 
Vv = 0.0048 ± 0.001 µm3/µm2). The same trend was observed with length-scale dependent roughness 
(Figure S2). 
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Figure 1. Atomic Force Microscopy (AFM) topographical images of the materials. Borosilicate glass 
(G), plexiglass (PG), hydroxyapatite (HA), titanium (TI) and polystyrene (PS) captured with the image 
size of 50 × 50 µm (A). Zoomed images of the materials with the size of 20 × 20 µm (B). 
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Table 1. Selected roughness parameters of materials used in the assays. Sdr describes the relative 
increase in surface area compared to the flat surface. Vv reflects void volume, describing the openness 
of the surface or surface porosity. 
Material Sdr (%) Vv (µm3/µm2) 
Borosilicate glass 0.3 ± 0.1 0.0048 ± 0.001 
Plexiglass 123 ± 20 0.62 ± 0.07 
Hydroxyapatite 58 ± 10 0.75 ± 0.08 
Titanium 9.0 ± 1.1 0.19 ± 0.02 
Polystyrene 3.0 ± 0.4 0.012 ± 0.002 
3.2. The Most Significant Time-Dependent Increase in Biofilm Formation Was Detected on HA 
Attachment of S. aureus ATCC 25923 onto all five materials was compared at three incubation 
time points (18, 42 and 66 h). The number of attached bacteria was expressed as log10 of viable 
CFU·(mL·cm2)−1. In the assay conditions, viable colonies increased temporally in a statistically 
significant manner only in two cases (PG and HA; from 18 to 42 h), while a non-significant trend 
implying temporal decrease in cell viability was observed with biofilms on G and TI (Figure 2). 
Comparisons between different materials at similar time points showed that S. aureus ATCC 25923 
was more prone to form biofilms on PS than on the other substrates. In addition, biofilm formation 
on PS was equally high after 18, 42 or 66 h. 
Figure 2. Formation of Staphylococcus aureus ATCC 25923 on five substrate materials. Bacterial 
attachment is expressed as log10 values of CFU·(mL·cm2)−1. Differences in attachment were assessed 
for a single material between different time points, and for a fixed time point between the different 
materials, using one-way ANOVA with Games–Howell post-test. *, significant difference (p < 0.05). 
Error bars denote the standard error of the mean (SEM) (n = 3). G, borosilicate glass; PG, plexiglass; 
HA, hydroxyapatite; TI, titanium; PS, polystyrene. 
3.3. Temporal Decrease in the Total PNAG Amount Was Detected in All Biofilms 
The exopolysaccharide amount was studied using a wheat germ agglutinin (WGA) conjugate 
that targets the poly-N-acetyl-β-(1-6)-glucosamine (PNAG) fraction of the biofilm matrix. Using the 
optimized staining conditions (described in Section 2.5), 18-, 42- and 66-h-old S. aureus ATCC 25923 
biofilms were treated with WGA conjugate, after being formed on the indicated five substrate 
materials. The PS-associated biofilms contained statistically more (p < 0.05) PNAG fraction than 
biofilms formed on G, PG or TI (Figure 3). A temporal decline (from 18 to 66 h) in the PNAG fraction 
was noted for all the tested substrate materials; the deepest decline was detected with biofilms on TI. 
The images presented in Figure 4 confirm the declining trend for PNAG in 18- versus 42-h-old 
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biofilms on G coupons, and illustrate the macrostructural temporal evolution from thick, intermittent 
regions (Figure 4A; 18 h) to a thinner, more cohesive PNAG network (Figure 4B; 42 h). 
 
Figure 3. Wheat germ agglutinin Alexa Fluor® 488 conjugate-based quantification of poly-N-acetyl-β-
(1-6)-glucosamine (PNAG) in S. aureus ATCC 25923. Differences in PNAG contents (expressed as 
relative fluorescence units (RFUs)) were assessed for a single material between different time points, 
and for a fixed time point between the different materials, using one-way ANOVA comparisons and 
Games–Howell post-tests for blank-corrected data points. *, significant difference (p < 0.05). Error bars 
denote the standard error of the mean (SEM) (n = 2). G, borosilicate glass; PG, plexiglass; HA, 
hydroxyapatite; TI, titanium; PS, polystyrene. 
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Figure 4. WGA-Alexa Fluor® 488 fluorescent conjugate-based imaging of the 18- (A) and 42-h-old (B) 
S. aureus ATCC 25923 biofilm matrix. Biofilms were formed on borosilicate glass coupons and the 
images were taken using Invitrogen™ EVOS® FL Imaging System. 
3.4. A Total of 66 Proteins Were Shared by All Biofilms 
The protein concentration and the number of proteins were first examined in all biofilm matrices 
at the indicated time points (18, 42 and 66 h). The clearest trend in time-dependent increase in the 
total protein concentration was detected for biofilms formed on G and HA (Figure 5A). For the PG- 
and PS-associated biofilms, the highest protein concentration was reached at the 42 h time point, 
although later declined at 66 h in both cases. 
Next, all the individual proteins were identified from the biofilm samples by trypsin shaving 
and LC–MS/MS analyses. The combined surfaceome catalogs based on two independent experiments 
enabled the identification of 460 proteins in total. An obvious trend of temporal increase in the 
number of the identified proteins was observed with biofilms formed on HA and TI (Figure 5B). At 
the 18 h time point, the highest number of proteins was identified from biofilms formed on PS (390 
proteins), and the lowest number with the biofilms formed on TI (76 proteins). The core surfaceomes 
(i.a., protein orthologs shared by all samples) defined for biofilms growing on different materials at 
a fixed time point indicated 67, 220 and 347 proteins that were shared by all 18, 42 and 66 h time point 
biofilms, respectively (Figure 6A). The number of proteins common to all biofilms (detected on every 
material at every time point) was 66 (Figure 6B). The highest number of proteins shared by all time 
points in fixed materials was obtained with the PG and PS biofilms (PG, 329 proteins; PS, 383 proteins) 
(Figure S3). 
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Figure 5. Protein concentrations mg·(mL·cm2)−1 (A) and the number of the identified matrix-associated 
proteins (detected in both replicates) (B) of the S. aureus ATCC 25923 biofilms. Differences in protein 
concentrations were assessed for a single material between different time points, and for a fixed time 
point between the different materials, using one-way ANOVA comparisons and Tukey post-tests for 
blank-corrected data points. *, significant difference (p < 0.05). Error bars denote the standard error of 
the mean (SEM) (n = 2). G, borosilicate glass; PG, plexiglass; HA, hydroxyapatite; TI, titanium; PS, 
polystyrene. 
 
Figure 6. Venn diagrams representing the shared surfaceome proteins present on all materials at fixed 
time points of growth (A) and the number of all identified proteins shared by each biofilm and 
material combination and time point (B). A three-dimensional principle component analysis (3D 
PCA) analysis indicating outliers and clusters (circled) nested within the identified material- and 
time-dependent biofilm surfaceomes (C). 
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3.5. Protein Moonlighters Formed the Largest Fraction of the Core Surfaceome 
Dynamics of relative protein abundance changes in each formed biofilm over time was 
investigated next by three-dimensional principal component analysis (3D PCA). Figure 6C shows 
two major clusters; the 42 h PS biofilm surfaceome together with those formed on each five materials 
for 66 h, while the rest of the 42 h biofilm surfaceomes (G, HA, PG and TI) and those associated with 
PG- and PS at the 18 h time point formed the second cluster. Biofilms formed on TI-, G- and HA-
coupons at the 18 h time point were clearly separated from the two main clusters, implying that these 
three materials affected the adherence in young biofilms (during 18 h). Altogether, the 3D PCA 
analysis revealed that TI, G and HA promoted specific surfaceome changes in biofilms already at the 
18 h time point. 
Table 2 illustrates changes in protein abundances in relation to time and different substrates. The 
most dominating proteins in all materials and time points were identified either as known or 
potential moonlighting proteins. Among these, the ribosomal proteins (r-proteins) formed the biggest 
group. Other moonlighters identified in all materials and time points included enzymes with a role 
in glycolysis (enolase (ENO); glyceraldehyde-3-phosphate dehydrogenase (GaPDH); 
triosephosphate isomerase (TPI); pyruvate kinase (PYK); pyruvate dehydrogenase E1 (PDHB); 
phosphoglycerate kinase (PGK); L-lactate dehydrogenase 1 (L-LDH) and alcohol dehydrogenase 
(ADH)), protein synthesis (elongation factor Tu (EfTU); elongation factor G (EfG) and elongation 
factor P (EfP)), and stress (chaperone protein (DnaK); universal stress protein (SAV1710), Usp and 
alkyl hydroperoxide reductase (AhpC)). Among these, the predicted abundances of EfTU, PGK, ENO 
and GaPDH reached the highest level at 66 h, which clearly exceeded those detected for the r-
proteins. The Clp family proteins (ClpP, ClpL, ClpC and ClpB) also displayed material-dependent 
variation; their abundances displayed temporal increase in all biofilm matrices. The Clp proteins 
were not detected at the 18 h time point of TI. 
A high number of different virulence factors and factors conferring increased resistance to one 
or several antibiotics were also detected (Table 2). From these, gamma-hemolysin component B 
(HlgB), leukocidin-like proteins (Luk1/2), IgG-binding proteins (Sbi and Spa) and immunodominant 
antigens (IsaA and IsaB) were among the high abundant proteins in all materials at each time point. 
Several regulatory proteins were present in one or several of the materials already in young 
biofilms—among these, the relative abundance of CcpA, CodY, SarR, SaeR, Rot, MsrR, Rex and VraR 
increased over time, reaching the highest level at the 66 h time point. Enzymes involved in 
maintaining the cellular redox state (e.g., peptide methionine sulfoxide reductase (MsrB)) were either 
present or absent at 18 h in biofilms but could be detected with higher identification scores in all 
biofilms at the 42 and 66 h time points (Tables S1 and S2). 
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Table 2. A heatmap comparing the intensity values (log10) of selected protein identification. 
Protein Name Acc. No. a 18 h 42 h 66 h 
PS G HA PG TI PS G HA PG TI PS G HA PG TI 
Bifunctional autolysin—AtlA Q6GI31                
Immunoglobulin G-binding protein A—Spa P38507                
Immunoglobulin-binding protein—Sbi Q6GE15                
Immunodominant antigen B—IsaB Q6GDG4                
Immunodominant antigen A—IsaA Q6GDN1                
Malate:quinone oxidoreductase 2—MQO2 Q6GDJ6                
Leukocidin-like protein 2—Luk2 Q6GF49                
Leukocidin-like protein 1—Luk1 Q6GF50                
Non-heme ferritin—FtnA Q99SZ3                
Foldase protein A—PrsA Q6GFL5                
Thioredoxin Q6GHU0                
Staphylococcal secretory antigen—SsaA Q99RX4                
Putative dipeptidase SAR1836 Q6GFV0                
Clp protease proteolytic subunit—ClpP Q6GIM3                
Clp ATPase ClpC Q99W78                
Clp ATPase ClpL Q6GDQ0                
Clp ATPase ClpB Q6GIB2                
Gamma-hemolysin component B—HlgB Q6GE12                
Protein RecA Q6GHF0                
Bone sialoprotein-binding protein—Bbp Q6GJA6                
Clumping factor B—ClfB Q6GDH2                
Clumping factor A—ClfA Q6GIK4                
Delta-hemolysin—HglD Q6GF37                
Virulence factor—EsxA Q99WU4                
ATP-dependent protease ATPase—HslU Q6GHI1                
Elastin-binding protein—EbpS Q6GGT1                
Fibrinogen-binding protein—FbnBP Q6GHS9                
Fibronectin-binding protein A—FnBPA Q6GDU5                
Ser-Asp repeat-containing protein C—SdrC Q6GJA7                
Ser-Asp repeat-containing protein D—SdrD Q8NXX6                
Catabolite control protein A—CcpA Q6GFX2                
Response regulator—CodY Q6GHI0                
Response regulator—SarA Q7A732                
Response regulator—Rot Q9RFJ6                
Response regulator—SarR Q9F0R1                
Response regulator—SarS Q7A872                
Response regulator—VraR Q7A4R9                
Response regulator—SaeR Q99VR7                
Response regulator—MsrR Q99Q02                
Response regulator—MraZ Q6GHQ7                
Response regulator—LytR P52078                
Response regulator—NrdR Q6GG20                
Response regulator—GraR Q6GJ11                
HTH-type transcriptional regulator—MgrA Q99VT5                
Redox-sensing repressor—Rex Q6GF26                
SOS response repressor—LexA Q9L4P1                
Oxygen regulatory protein—NreC Q99RN8                
Regulatory protein—Spx Q6GI88                
Histidine protein kinase—SaeS Q99VR8                
RNA polymerase sigma factor SigA Q99TT5                
Anti-sigma-B factor antagonist—RsbV Q6GF07                
Iron-regulated surface determinant—IsdB Q6GHV7                
Lysostaphin resistance protein A—LyrA Q6GEA0                
Methicillin-resistance protein—FmtA Q6GI27                
Conserved virulence factor B—CvfB Q99U93                
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DegV domain-containing protein SAR1438 Q6GGY2                
Signal transduction protein TRAP Q6GFM2                
Staphopain A (cysteine protease)—SspP Q6GFE8                
Ferrochelatase—HemH Q6G8A3                
Phospholipase C—PlC Q5HEI1                
Methicillin resistance-associated—FemA Q99UA7                
Methicillin resistance-associated—FemB Q6GH30                
Probable cell wall amidase—LytH Q7A588                
ATP-dependent protease subunit—HslV Q6GHI2                
CtpA-like serine protease Q6GGY8                
HtrA-like serine protease Q6GI62                
Hydrolase encoded by the agr operon P55177                
Probable thiol peroxidase Q6GFZ4                
Uncharacterized oxidoreductase SAR2567 Q6GDV6                
Peptide methionine sulfoxide reductase MsrB Q6GGY4                
Heme-dependent peroxidase (SAV0587) Q99W24                
Thioredoxin reductase Q6GB66                
NADPH-dependent oxidoreductase Q6GJR6                
Multicopper oxidase—Mco Q6GIX3                
Nitric oxide synthase oxygenase Q6GFE2                
Putative NAD(P)H nitroreductase (SAV2523) Q99RB2                
FMN-dependent NADPH-azoreductase Q99W49                
Staphylocoagulase—Coa P17855                
Iron-sulfur cluster repair protein—ScdA Q6GK53                
Urease accessory protein G—UreG Q99RX9                
ATP synthase epsilon chain Q6GEX3                
ATP synthase subunit delta Q6GEW9                
ATP synthase gamma chain Q99SF4                
30S ribosomal protein S1 Q6GGT5                
30S ribosomal protein S10 Q931G5                
30S ribosomal protein S11 Q6GEK8                
30S ribosomal protein S12 Q6GJC3                
30S ribosomal protein S13 Q6GEK7                
30S ribosomal protein S15 Q99UJ9                
30S ribosomal protein S16 Q6GHJ7                
30S ribosomal protein S17 Q8NVB4                
30S ribosomal protein S18 Q6GJV1                
30S ribosomal protein S19 Q6GEI7                
30S ribosomal protein S2 Q6GHH9                
30S ribosomal protein S20 Q99TR3                
30S ribosomal protein S21 Q6GGC5                
30S ribosomal protein S3 Q6GEI9                
30S ribosomal protein S4 Q6GFY8                
30S ribosomal protein S5 Q6GEK0                
30S ribosomal protein S6 Q6GJV3                
30S ribosomal protein S7 Q6GJC2                
30S ribosomal protein S8 Q6GEJ7                
30S ribosomal protein S9 Q6GEL8                
50S ribosomal protein L1 Q6GJD0                
50S ribosomal protein L10 Q6GJC9                
50S ribosomal protein L11 Q6GJD1                
50S ribosomal protein L13 Q99S51                
50S ribosomal protein L14 Q99S31                
50S ribosomal protein L15 Q6GEK2                
50S ribosomal protein L16 Q99S28                
50S ribosomal protein L17 Q99S46                
50S ribosomal protein L18 Q99S37                
50S ribosomal protein L2 Q6GEI6                
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50S ribosomal protein L20 Q6GG27                
50S ribosomal protein L21 Q99TK6                
50S ribosomal protein L22 Q99S26                
50S ribosomal protein L23 Q99S23                
50S ribosomal protein L24 Q6GEJ4                
50S ribosomal protein L25 Q99WA2                
50S ribosomal protein L27 Q931Q3                
50S ribosomal protein L28 Q6GHL1                
50S ribosomal protein L29 Q6GEJ1                
50S ribosomal protein L3 Q6GEI3                
50S ribosomal protein L30 Q6GEK1                
50S ribosomal protein L31 Q6GEV5                
50S ribosomal protein L35 Q6GG26                
50S ribosomal protein L4 Q6GEI4                
50S ribosomal protein L5 Q99S33                
50S ribosomal protein L6 Q99S36                
50S ribosomal protein L7/L12 Q6GJC8                
50S ribosomal protein L9 Q6GKT0                
Elongation factor Tu—EfTU Q6GJC0                
Elongation factor G—EfG Q6GJC1                
Translation initiation factor IF-3—InfC Q6GG25                
Translation initiation factor IF-2—InfB Q6GHG6                
Elongation factor P—EfP Q6GGH0                
Glyceraldehyde-3-phosphate dehydrogenase Q6GIL8                
Enolase—ENO Q6GIL4                
Phosphoglycerate kinase—PGK Q6GIL7                
Pyruvate kinase—PYK Q6GG09                
Fructose-bisphosphate aldolase class 1—FBA Q6GDJ7                
Pyruvate dehydrogenase E1—PDHB Q6GHZ1                
Triosephosphate isomerase—TPI Q6GIL6                
ATP-dependent 6-phosphofructokinase—PFK Q6GG08                
2,3-phosphoglycerate mutase—PPGM Q6GE17                
Aconitase A—AcnA Q6GH55                
L-lactate dehydrogenase 1—L-LDH Q6GK73                
D-lactate dehydrogenase—D-LDH Q6GDS2                
Alkaline shock protein 23—Asp23 Q6GEP7                
Alcohol dehydrogenase—ADH Q99W07                
Trigger factor—Tf Q6GG30                
DNA-directed RNA polymerase—RpoB Q6GJC5                
Alkyl hydroperoxide reductase—AhpC Q6GJR7                
Alkyl hydroperoxide reductase—AhpF Q6GJR8                
Chaperone protein—GroEL Q6GF43                
Chaperone protein—DnaK Q6GGC0                
Chaperone protein—DnaJ Q6GGC1                
10 kDa chaperonin Q6GF42                
Universal stress protein (SAV1710)—Usp Q99TF3                
Superoxide dismutase [Mn/Fe] 1—SodA Q6GGE6                
DNA mismatch repair protein—MutL Q93T05                
Thermonuclease Q5HHM4                
Glutamine synthetase Q6GHC6                
Color gradient from red to green is used to indicate decreasing intensity values. 
.a Acc. No., accession numbers were retrieved from the UniProt protein database. In red are proteins 
involved in adherence and/or adherent growth (biofilm formation), and in blue are adhesive 
moonlighters. 
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3.6. Greatest Time-Dependent Variations Were Observed for TI- and HA-Associated Surfaceomes 
Comparing the number of uniquely identified proteins at different time points of growth 
revealed the greatest differences in TI- and HA-associated surfaceomes (Figure S3). These 
surfaceomes displayed a relatively high number of specific proteins at 66 h (HA, 74 proteins; TI, 169 
proteins) and proteins shared by these two matrices at the 42 and 66 h time points (HA, 142 proteins; 
TI, 164 proteins) could not be identified in other biofilm matrices. Of note, at the 18 h time point, TI-
associated biofilm cell surfaces were devoid of several proteins that were identified from other 
biofilms at this time point. 
The classically secreted cell wall/membrane-anchored adhesins were either present or absent in 
one or several of the investigated biofilms at the 18 h time point (Table 2). These included the 
fibronectin (FnBPA) and fibrinogen binding proteins (FbnBP). For instance, FnBPA was not detected 
in PS, HA or TI biofilms, while HA biofilms lacked the FbnBP adhesion at this growth stage (18 h). 
The bone sialoprotein-binding protein (Bbp) was not present in G and TI biofilms (18 h), while elastin 
binding proteins S (EbpS) was detected only in PS and G biofilms. The clumping factors A and B 
(ClfA, ClfB) were also differently abundant on the tested materials at the 18 h time point: ClfA was 
specific to PS and PG biofilms, while ClfB was detected on every material except on TI. On the other 
hand, adhesins that were not detected at the 18 h time point (or detected with lower abundances) 
could be identified with reasonably high identification scores at the later time points of growth (42- 
and/or 66 h). Such proteins included Bbp, FbnBP and the clumping factors ClfA and ClfB. In addition, 
FnBPA was not identified in any biofilm surfaceomes at the later time point (66 h). Glutamine 
synthetase, a potential moonlighting adhesin, was specifically identified only in TI biofilms at each 
time point of growth. 
3.7. Antibiotic Susceptibility Depends on the Composition of the Biofilm Surfaceome 
Based on the observed biofilm characteristics (number of cells, PNAG and protein content) the 
HA- and TI-associated biofilms were further tested with different antibiotics. To this end, 18 and 66 
h biofilms were exposed to four different antimicrobial (vancomycin, penicillin G, doxycycline, 
levofloxacin) agents for 2 or 24 h. As shown in Figure 7 the viable cell counts (CFUs) decreased in a 
statistically significant manner (p < 0.05 and p < 0.001) in all cases with the 24-h-long exposure when 
compared to the TSB-treated control coupons containing biofilm cells. A comparison of the used 
materials indicated that the 66-h-old biofilms on HA exposed to antibiotics for 2 h were more 
susceptible than biofilms on TI in all of the cases (Table 3). In general, biofilms formed on HA seemed 
to be more susceptible than in TI to antibiotics in most of the cases (in eight out of 11). When taking 
the biofilm age-related differences into account, the 66-h-old biofilms were found more susceptible 
than the 18-h-old biofilms in three out of 10 cases. In most of the cases (in seven out of 10), the younger 
biofilms (18 h) were more susceptible than the older (66 h) biofilms. Comparing the antibiotic 
treatment times indicated that increasing the exposure time from 2 to 24 h resulted in reduced 
chemotolerance in each biofilm age- and material-combination. From the tested antibiotics, 
levofloxacin at a final concentration of 90 µM was found as the most efficient in reducing the viable 
colonies from biofilms formed on both materials. The most efficient antibiotic treatment was obtained 
with 18-h-old biofilms exposed to levofloxacin for 24 h. 
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Figure 7. The chemotolerance of 18- and 66-h-old S. aureus ATCC 25923 biofilms formed on 
hydroxyapatite, HA (A) and titanium, TI (B) and exposed to several antibiotics for 2 or 24 h. The 
results are expressed as log10 values of CFU·(mL·cm2)−1. Plain white and dark grey bars illustrate 18- 
and 66-h-old biofilms (respectively) with 2-h-long antibiotic exposure, while striped white and dark 
grey bars illustrate 18- and 66-h-old biofilms (respectively) with 24-h-long antibiotic exposure. The 
results of antibiotic-treated biofilms were compared to TSB-treated biofilms. The statistical analysis 
was performed by using unpaired t-tests with Welch’s correction. * p < 0.05 and *** p < 0.001 were 
considered statistically significant and highly significant, respectively. Error bars denote the standard 
error of the mean (SEM) (n = 2). 
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Table 3. The chemotolerance of S. aureus ATCC 25923 as quantified using the log reduction of viable 
counts. The 18-h- and 66-h-old biofilms were formed on hydroxyapatite (HA) and titanium (TI), and 
exposed to penicillin G, levofloxacin, doxycycline and vancomycin. 
Biofilm 
Age 
Biofilm 
Formed 
on 
Exposure 
Time  
Penicillin G 
(2.0 µM) a 
Levofloxacin 
(90.0 µM) a 
Doxycycline 
(4.0 µM) a 
Vancomycin 
(5.0 µM) a 
18 h HA 2 h 0.10 ± 0.28 
 
0.56 ± 0.06 
 
0.08 ± 0.15 
 
0.03 ± 0.31 
 
18 h TI 2 h 0.01 ± 0.19 1.39 ± 0.05 
***,    
0.59 ± 0.21 
*,  
−0.17 ± 0.25 
18 h HA 24 h 2.32 ± 0.18 
***,   , Ω 
3.09 ± 0.04 
***,   , Ω Ω Ω 
2.00 ± 0.14 
*, , Ω Ω Ω 
0.65 ± 0.09 Ω 
18 h TI 24 h 1.28 ± 0.08  
 
2.18 ± 0.15 
  , Ω Ω Ω 
1.08 ± 0.20 Ω 0.33 ± 0.09 
66 h HA 2 h 0.42 ± 0.04 
* 
0.64 ± 0.24 
*,  
0.31 ± 0.08 0.61 ± 0.11 
*,  
66 h TI 2 h 0.07 ± 0.15 
 
0.46 ± 0.08 0.39 ± 0.06 0.24 ± 0.12 
66 h HA 24 h 1.82 ± 0.24 
*, Ω Ω Ω 
2.35 ± 0.07 
***, Ω 
1.32 ± 0.20 
Ω 
0.88 ± 0.38 
66 h TI 24 h 0.94 ± 0.18 
Ω 
1.76 ± 0.14 
Ω Ω Ω 
1.62 ± 0.04 
*, , Ω Ω Ω 
1.67 ± 0.03 
Ω 
a The numbers refer to logR values (±SEM) indicating the difference between antibiotic- and medium-
treated coupons. *, p < 0.05 and ***, p < 0.001; differences between HA and TI, when the biofilm age 
and exposure time are the same. , p < 0.05 and   , p < 0.001; differences between the 18- and 66-h-
old biofilms when the exposure times and the materials are same. Ω, p < 0.05 and Ω Ω Ω, p < 0.001; 
differences between exposure times (2 h and 24 h) when the biofilm age and the materials are the 
same. The statistical analyses were performed using unpaired t-tests with Welch’s correction. 
A combination treatment of trypsin and levofloxacin on 18- and 66-h-old biofilms formed on HA 
was tested. For this purpose, biofilms were first treated with trypsin (51.9 ng·µL–1) followed by a 90 
µM levofloxacin treatment. Comparison of the results with the two controls (biofilms treated with 
TSB or 100 mM TEAB followed by 90 µM levofloxacin) revealed that the trypsin treatment alone did 
not benefit biofilm eradication (Figure 8). Statistically highly significant differences (p < 0.001) were 
only acquired when biofilms were treated with trypsin and levofloxacin in comparison with the TSB-
treated biofilms. Additionally, there was no difference between the trypsin- and levofloxacin-treated 
18- and 66-h-old biofilms, indicating that the protein-dependent matrix network was already well-
established at the 18 h time point. 
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Figure 8. Viability of 18- and 66-h-old S. aureus ATCC 25923 biofilms treated with trypsin and 90 µM 
levofloxacin (LVX), triethylammonium bicarbonate buffer (TEAB) (trypsin buffer) and 90 µM 
levofloxacin or tryptic soy broth (TSB). The number of viable cells is expressed as log10 values of CFU 
(mL·cm2)–1. The statistical analysis was performed using unpaired t-tests with Welch’s correction. 
Highly significant change in viability (p < 0.001) compared to (a) TSB at 18 h time point and (b) TSB 
at 66 h time point. Error bars denote the standard error of the mean (SEM) (n = 2). 
4. Discussion 
It is known that biofilm formation of S. aureus depends, among other factors, on the functional 
characteristics of the indwelling medical device and the specific surface components of the bacterium. 
However, many biofilm studies have traditionally utilized PS-based surface materials as the substrate 
for promoting adherent/biofilm growth. The biggest drawback of such studies is that the obtained 
results are not directly applicable to other clinically relevant substrate materials. In addition, instead 
of systematic studies focusing on the biofilm substrates or the biofilm matrix components, the 
majority of the studies have investigated the role of the individual materials or specific surface-
anchored components of the adhering S. aureus. The present study aimed at filling this gap in 
knowledge by exploring structural features of five clinically pertinent materials and complementing 
the findings with in-depth surfaceomics of S. aureus ATCC 25923 biofilms growing on those materials. 
4.1. Structural Features and the Impact of PNAG on Biofilm Growth 
The surface analyses of the tested substrate materials revealed considerable differences in 
roughness, which, however, did not correlate with the biofilm formation efficiency. This suggests 
that other physicochemical factors (such as surface charge and surface energy) might have played a 
role in the biofilm–substrate interactions and could explain the material-dependent changes in the 
number of exopolysaccharides (PNAG fraction) and protein. poly-N-acetyl-β-(1–6)-glucosamine 
(PNAG; also referred to as polysaccharide intercellular adhesin (PIA)) is a major exopolysaccharide 
in the Staphylococcus aureus biofilm matrix. It is partially deacetylated, and its synthesis is mediated 
by the icaADBC locus [64,65]. Biofilms on PS and HA materials had the highest amount of PNAG at 
the 18 h time point, but this content was reducing over time in all materials, with the deepest drop in 
TI biofilms. In contrast, the protein amount was increasing towards the end of the growth. The most 
significant increase in protein amount was detected with G and HA biofilms, while the highest 
elevation in the number of proteins was detected with TI and HA biofilms. These findings suggest 
that PNAG has a more important role than proteins in coordinating the adherence of the cells in 
young biofilms (18 h) on PS and HA. In contrast, the protein role would switch to be more crucial at 
the later stages of biofilm formation (contributing to material-specific adherence and/or maintaining 
biofilm integrity/stability). PNAG has a net positive charge, which, besides promoting intercellular 
interactions by binding to the negatively charged surfaces of neighboring cells, might additionally 
have stimulated the adherence to negatively charged surfaces (such as those provided by the 
hydrophilic PS). Shifts in extracellular pH due to metabolic fluctuations may have also affected the 
PNAG content, as pH has been shown to control the EPS stability and thereby the mechanical 
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properties of the S. aureus SH1000 biofilm [66]. PNAG is known to affect the attachment of 
staphylococcal biofilms, pathogenesis [67], resistance to phagocytosis, polymorphonuclear 
leucocytes [68,69] and antibiotic tolerance [70]. We suggest that among the materials studied here, PS 
and HA provide the best support for PNAG-stimulated biofilm growth. 
4.2. The Accessory and Core Surfaceomes of the S. aureus ATCC 25923 Biofilms 
Greatest variations in surfaceomes were detected for TI-, HA- and G-associated biofilms already 
at the 18 h time point. Virulence factors such as hemolysin HlgB and EsxA (a chaperone and/or an 
adaptor protein, which interacts with host receptor proteins and interferes with host cell apoptotic 
pathways) [71,72], were found moderately abundant in all biofilms at the 42 and 66 h time points. 
Staphopain A (SspP), detected here in all biofilms (except on HA, at 18 h), has been proposed to 
increase bacterial persistence through, e.g., degrading the antimicrobial human peptide LL-37 [73]. 
Immunodominant antigens IsaA and IsaB were dominating proteins in all biofilm samples. IsaA has 
been proposed to have autolytic activity [74], while elevated IsaB-levels promote the virulence and 
persistence of MRSA [75]. Increased abundance of IsaA has also been reported for Staphylococcus 
epidermidis biofilms formed on TI [76], implying that this antigen could have mediated S. aureus 
biofilm formation on the selected materials in our study. Bifunctional autolysin (AtlA), identified on 
all materials at every time point, has been reported to be responsible for initial attachment in biofilm 
formation, bacterial cell wall degradation and cell separation during cell division [46,77]. In addition, 
this autolysin is also reported with a potential role in FnBP-mediated biofilm maturation [78]. Our 
findings suggest that FnBPA could be important in earlier stages of biofilm formation (in young 
biofilms, at the 18 h time point), whereas the abundance of FbnBP in older biofilms implies this 
adhesin might have a more prominent role in biofilm maturation. 
Staphylococcal secretory antigen (SsaA) was one of the most abundant secreted antigens 
detected in all biofilm samples (except on TI); this immunodominant antigen is suggested to be 
involved in biofilm growth and biofilm-related infections [79,80]. The immunoglobulin-binding 
protein A (Spa), identified on all materials at every time point, has been shown to be in a pivotal role 
in biofilm formation [81]. Other potential surface adhesins, such as Ser-Asp repeat-containing protein 
C (SdrC), ClfA, ClfB, Bbp and EbpS detected here in initial stages of biofilm growth on one or several 
of the tested materials, could also play a role in promoting initial adherence to the tested materials. 
Glutamine synthetase, with an ability to bind fibronectin, laminin, collagen I and plasminogen [82], 
was specifically identified only in TI-associated biofilms, implying that biofilms formed on this 
substrate could interfere with the host immune defense system. 
4.3. The Surface-Associated Moonlighters Dominate in All Studied Biofilms 
The cytoplasmic proteins with predicted multitasking functions [82,83] formed the biggest 
group among all identified proteins, independent of the biofilm substrate used. The presence of 
cytoplasmic proteins in the extracellular milieu has been widely explained with cell lysis/leakage. 
However, this interpretation seems to be too simple, since several lines of evidence imply the 
existence of a yet unknown mechanism controlling cytoplasmic protein excretion. For example, it has 
been noted that cytoplasmic protein excretion is increased when the autolysins are up-regulated and 
peptidoglycan cross-linking is decreased [84]. Cell lysis in S. aureus biofilms has been shown to 
depend on the presence of the major autolysin Atl, the holin/antiholin system CidABC and LrgAB 
[78,85–87]. Atl has been shown to be strongly upregulated in moderately aged S. aureus biofilms, 
which resulted in strong lysis and accumulation of intracellular proteins in the biofilm matrix [47]. 
Thus, besides the conventional autolysin activity, AtlA can also control the excretion of 
cytoplasmic proteins (e.g., EfTU) to the cell surface; a process that is not random, but suggested to 
involve selection based on certain sequence motifs (e.g., α-helices) [84,87–89]. The Atl-mediated 
protein export could also occur in vivo in S. aureus, indicated by recent results in the post-arthroplasty 
joint infection model (hypodermic stainless-steel rod) where higher levels of cytoplasmic proteins 
were found, compared to the classical surface adhesins or other classically secreted proteins [48]. 
From the cytoplasmic proteins, GaPDH has been detected with increased abundances in S. epidermidis 
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biofilms formed on TI [76], indicating that this moonlighter could be important for biofilm formation 
or stability of the formed biofilms. Besides their conventional roles in cytoplasm, the cytoplasmic 
proteins are reported to have also adhesive (to plasminogen, laminin, Caco-2-cell, mucin, EPS-
derived mannan or rhamnose), immunomodulatory and/or biofilm formation stimulating functions 
[90–94]. 
Here, the r-protein moonlighters, bearing a high net positive charge with high affinity towards 
anionic cell wall components (eDNA and anionic metabolites), formed the biggest group of the 
identified moonlighting proteins. This is supported by [47], showing that r-proteins and several 
secreted virulence proteins (both having a strong positive charge) are embedded in the acidic S. 
aureus biofilm matrix. Acidic conditions are generated by the release of fermentation end-products as 
a response to oxygen limitation in the biofilms. In that study, the r-proteins were suggested to 
contribute to the pH-dependent stability of the biofilms. The r-proteins are classically involved in 
translation, but after associating with cell surfaces, they could also function as a defensive mechanism 
in response to external challenges originating from the host immune system, antibiotics or other 
challenges, as previously reported by [95]. This has been supported by a recent proteomic study 
reporting that the production of r-proteins is increased in response to an antibacterial agent, 
quinolonyl-oxazolidinone [96]. 
Our study also indicated the presence of several regulatory proteins normally acting in 
intracellular milieu by coordinating biofilm growth, virulence and/or drug resistance [97] at biofilm 
cell surfaces. S. aureus is also reported to use membrane vesicles (MVs) to transfer regulators, 
virulence factors and drug resistance enzymes in a protected and concentrated manner [98–102]. 
Regulator proteins SarR, SarS and Rot, as well as r-proteins, malate:quinone oxidoreductase 2 
(MQO2), hemolysins, leukocidins, certain moonlighters (EfG, EfTU, chaperone protein DnaJ, Usp, 
PYK, ENO, PDHB, ATP synthase subunit beta), foldase protein A (PrsA) and penicillin-binding 
protein were previously identified from MVs isolated from S. aureus 06ST1048 [101]. Notably, 
leukocidins have been shown to be efficiently produced also during chronic infection in vivo [48], 
which further suggests that S. aureus can actively modulate the host immune system even protected 
within the biofilm. Thus, it can be hypothesized that these virulence factors are sorted into MVs for 
protected export, together with necessary moonlighters, aiming at maintaining the cohesion and 
viability of the biofilm community in vivo. 
4.4. Older Biofilms Are Not Always More Tolerant Than Younger Biofilms 
Our findings suggested that PS, G and PG could provoke protein-dependent antibiotic 
resistance, as the enzymes lysostaphin resistance protein A (LyrA) and methicillin resistance-
associated FemA/B and FmtA [103–105] were detected in PS, PG and/or G biofilms already at the 18 
h time point, implying that biofilms on other materials may be more susceptible to certain antibiotics. 
In our study, chemotolerance tests were executed with different antibiotics covering a broad 
spectrum of mechanisms of action: vancomycin (glycopeptide: inhibits cell wall synthesis by forming 
complexes with peptidoglycan precursors [106]), penicillin G (B-lactam: inhibits cell wall synthesis 
via preventing peptidoglycan polymerization [107]), doxycycline (tetracycline: inhibits protein 
synthesis by binding to the 30S subunit of the bacterial ribosome [108]) and levofloxacin 
(fluoroquinolone: inhibits bacterial DNA gyrase and topoisomerase IV in Gram-negative and Gram-
positive bacteria, respectively, and blocking DNA replication [109]). Furthermore, levofloxacin, 
vancomycin and doxycycline are used as a part of treatment regimen in managing prosthetic joint 
infections caused by Staphylococcus spp. Usually, vancomycin is administered intravenously for the 
first two weeks after the surgical therapy (if oxacillin-, methicillin- or rifampicin-resistance has been 
observed), while doxycycline and levofloxacin are given per oral as a continuation therapy (a total 
duration of antibiotic treatment is 12 weeks) [110]. Our results were in accordance with the results 
obtained by [111], where several antibiotics were tested against Staphylococcus aureus ATCC 25923. 
Therein, levofloxacin was the most effective, followed by doxycycline, penicillin G and vancomycin 
(least active). In our study, levofloxacin was the most effective, while the second most active was 
penicillin G or doxycycline depending on the biofilm age, used substrate material or exposure time 
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of the antibiotic. Least active was vancomycin, as well. Furthermore, in another study, doxycycline 
displayed higher activity than vancomycin against different Staphylococcus aureus clinical isolates 
[112]. 
The results also revealed that in many cases, biofilms formed on HA were more susceptible to 
antibiotics than biofilms on TI. Unexpectedly, the 66 h biofilms were not always more tolerant than 
those grown for 18 h, which may suggest that other surface factors, such as the r-protein moonlighters 
or other moonlighting proteins could have contributed to the observed phenotypes. 
4.5. Several Biofilm Surfaceome Proteins Are Important for Successful Infection 
Hemolysins, leukocidins, stress proteins (AhpC/F, Usp, SodA), resistance (FmtA), chaperones 
(ClpL, ClpC, ClpB, DnaK and GroEL) and response regulators (VraR, CodY and CcpA) identified 
here already at 18-h-old biofilms were recently suggested to be involved in host–pathogen 
interactions in vivo [113]. Several of these proteins were also identified as secreted and/or matrix-
associated proteins in an implant-associated biofilm in vivo infection model [48]. In addition, the Clp 
family proteins are reported to be important for biofilm formation and virulence [114]. The 
appearance of ClpP at the cell surface is interesting, as the enzyme can be activated by an 
acyldepsipeptide antibiotic into a non-specific protease capable of killing S. aureus persisters [115]. 
5. Conclusions 
The present study indicated the importance of PNAG and dedicated cell wall/membrane-
anchored proteins during the initial stages of biofilm formation. The recycling of cytoplasmic proteins 
as moonlighting components could benefit biofilm population by increasing the integrity, stability 
and drug resistance of the cells. As the development of the protein matrix was slowest on HA and TI, 
our study proposes that these substrates could provide a good starting point for generating new 
clinical materials with enhanced anti-biofilm features. Prior to this, as biofilms formed on HA were 
found to reach sufficient maturity already at the 18 h time point, in-depth surfaceome analysis on this 
material should be investigated also at earlier time points. Classical surface proteins have been 
considered as the most attractive targets in drug design against bacterial pathogens. However, this 
research should be expanded to also include non-classical moonlighters, as many of these can 
contribute to virulence and drug tolerance. Thus, understanding mechanisms coordinating the 
moonlighting activity would not only provide fundamental insights into bacterial gene regulation, 
but it may also shed better insight into new strategies aimed at designing novel anti-biofilm 
agents/materials. 
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